Marie O Halloran1,2, Catherine Boyle1, Brona Kehoe1, Emmanouil Bagkeris3, Paddy Mallon4, Frank A Post5, Jamie Vera6, Ian Williams7, Jane Anderson8, Alan Winston9, Memory Sachikonye10, Caroline Sabin3, Marta Boffito9,11. 1. Pharmacy Department, Mater Misericordiae University Hospital, Dublin, Ireland. 2. School of Pharmacy, Trinity College Dublin, Dublin, Ireland. 3. Institute for Global Health, University College London, London, United Kingdom. 4. School of Medicine, University College Dublin, Dublin, Ireland. 5. King's College Hospital NHS Foundation Trust, London, United Kingdom. 6. Brighton and Sussex University Hospitals NHS Trust, Brighton, United Kingdom. 7. NHS Mortimer Market Centre, London, United Kingdom. 8. Homerton University Hospital NHS Foundation Trust, London, United Kingdom. 9. Division of Infectious Diseases, Imperial College London, London, United Kingdom. 10. iBase, London, United Kingdom. 11. St Stephen's AIDS Trust, Chelsea and Westminster Hospital, London, United Kingdom.
Abstract
BACKGROUND: Polypharmacy (use of ≥ five medications) increases the risk of drug-drug interactions and can lead to negative health outcomes. This study aimed to review the medications of people living with HIV (PLWH) and HIV-negative controls in the POPPY study and evaluate the frequency of polypharmacy and potential drug-drug interactions (PDDIs). METHODS: PDDIs between non-antiretroviral (ARV) drugs were analysed using the Lexicomp® database, and PDDIs between non-ARV and ARV drugs using the Liverpool drug interaction database. Between-group differences were assessed using χ2, Mann-Whitney U and Kruskal-Wallis tests. RESULTS: This analysis included 698 PLWH ≥50 years, 374 PLWH <50 years and 304 HIV-negative controls ≥50 years. The prevalence of polypharmacy was 65.8% in older PLWH, 48.1% in younger PLWH and 13.2% in the HIV-negative group. When ARVs were excluded, 29.8% of older PLWH and 14.2% of younger PLWH had polypharmacy. The prevalence of ≥1 PDDI involving non-ARV drugs was 36.1%, 20.3% and 16.4%, respectively, in older PLWH, younger PLWH and HIV-negative controls. In PLWH the prevalence of ≥1 PDDI involving ARV and non-ARV drugs was 57.3% in older PLWH and 32.4% in younger PLWH. CONCLUSIONS: Polypharmacy and PDDIs involving non-ARV/ARV drugs and non-ARV/non-ARV drugs were common among older PLWH, highlighting the need for increased awareness and additional research on all types of PDDI.
BACKGROUND: Polypharmacy (use of ≥ five medications) increases the risk of drug-drug interactions and can lead to negative health outcomes. This study aimed to review the medications of people living with HIV (PLWH) and HIV-negative controls in the POPPY study and evaluate the frequency of polypharmacy and potential drug-drug interactions (PDDIs). METHODS: PDDIs between non-antiretroviral (ARV) drugs were analysed using the Lexicomp® database, and PDDIs between non-ARV and ARV drugs using the Liverpool drug interaction database. Between-group differences were assessed using χ2, Mann-Whitney U and Kruskal-Wallis tests. RESULTS: This analysis included 698 PLWH ≥50 years, 374 PLWH <50 years and 304 HIV-negative controls ≥50 years. The prevalence of polypharmacy was 65.8% in older PLWH, 48.1% in younger PLWH and 13.2% in the HIV-negative group. When ARVs were excluded, 29.8% of older PLWH and 14.2% of younger PLWH had polypharmacy. The prevalence of ≥1 PDDI involving non-ARV drugs was 36.1%, 20.3% and 16.4%, respectively, in older PLWH, younger PLWH and HIV-negative controls. In PLWH the prevalence of ≥1 PDDI involving ARV and non-ARV drugs was 57.3% in older PLWH and 32.4% in younger PLWH. CONCLUSIONS: Polypharmacy and PDDIs involving non-ARV/ARV drugs and non-ARV/non-ARV drugs were common among older PLWH, highlighting the need for increased awareness and additional research on all types of PDDI.
Authors: Asante R Kamkwalala; Ankita Garg; Upal Roy; Avery Matthews; Jose Castillo-Mancilla; Jordan E Lake; Giada Sebastiani; Michael Yin; Todd T Brown; Angela R Kamer; Douglas A Jabs; Ronald J Ellis; Marta Boffito; Meredith Greene; Sarah Schmalzle; Eugenia Siegler; Kristine M Erlandson; David J Moore Journal: AIDS Res Hum Retroviruses Date: 2021-09-20 Impact factor: 2.205
Authors: Christina K Psomas; Donald R Hoover; Qiuhu Shi; Todd T Brown; David E Vance; Susan Holman; Michael W Plankey; Phyllis C Tien; Kathleen M Weber; Michelle Floris-Moore; Hector H Bolivar; Elizabeth T Golub; Marcia McDonnell Holstad; Kendra K Radtke; Bani Tamraz; Kristine M Erlandson; Leah H Rubin; Anjali Sharma Journal: J Acquir Immune Defic Syndr Date: 2022-07-01 Impact factor: 3.771
Authors: Jason J Schafer; Neha S Pandit; Agnes Cha; Emily Huesgen; Melissa Badowski; Elizabeth M Sherman; Jennifer Cocohoba; Ayako Shimada; Scott W Keith Journal: Open Forum Infect Dis Date: 2020-12-18 Impact factor: 3.835
Authors: Meredith Greene; Janet Myers; Judy Y Tan; Cinthia Blat; Allison O'Hollaren; Francisco Quintanilla; Priscilla Hsue; Mary Shiels; Mary Lawrence Hicks; Bill Olson; Janet Grochowski; Jon Oskarsson; Diane Havlir; Monica Gandhi Journal: J Int Assoc Provid AIDS Care Date: 2020 Jan-Dec
Authors: C Okoli; A Schwenk; M Radford; M Myland; S Taylor; A Darley; J Barnes; A Fox; F Grimson; I Reeves; S Munshi; A Croucher; N Boxall; P Benn; A Paice; J van Wyk; S Khoo Journal: HIV Med Date: 2020-07-15 Impact factor: 3.180